GSK discontinued manufacturing its Flovent HFA and Flovent Diskus inhalers in January, leading to an increase in asthma-related ICU admissions, inpatient admissions, and ED visits. Study results from Epic Research showed a rise in these encounters after the discontinuation of Flovent. The study analyzed data from over 3 million patients with asthma who had prescriptions for fluticasone propionate. The findings highlight the challenges faced by doctors and patients in navigating the healthcare system. Epic Research conducts studies using data from hospitals and clinics that use the Epic System’s electronic health record software, with teams comprised of clinicians and data scientists.
Source link
ICU, inpatient admission rates related to asthma rise following Flovent discontinuation
